Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prodrugs | 10 | 2022 | 30 | 4.160 |
Why?
|
| Annexin A5 | 12 | 2022 | 24 | 3.640 |
Why?
|
| Recombinant Fusion Proteins | 13 | 2018 | 233 | 2.740 |
Why?
|
| Nanotubes, Carbon | 6 | 2024 | 50 | 2.570 |
Why?
|
| Carbon-Sulfur Lyases | 9 | 2017 | 16 | 1.690 |
Why?
|
| Phototherapy | 4 | 2024 | 28 | 1.570 |
Why?
|
| Breast Neoplasms | 7 | 2024 | 459 | 1.480 |
Why?
|
| Escherichia coli | 4 | 2020 | 337 | 1.380 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 1319 | 1.230 |
Why?
|
| Phosphatidylserines | 5 | 2022 | 20 | 1.060 |
Why?
|
| Purine-Nucleoside Phosphorylase | 3 | 2015 | 5 | 1.010 |
Why?
|
| Neovascularization, Pathologic | 4 | 2017 | 149 | 1.000 |
Why?
|
| Hyperthermia, Induced | 2 | 2018 | 30 | 0.980 |
Why?
|
| Mice, Inbred BALB C | 2 | 2024 | 276 | 0.950 |
Why?
|
| Cytosine Deaminase | 3 | 2015 | 3 | 0.950 |
Why?
|
| Tubulin Modulators | 2 | 2015 | 17 | 0.940 |
Why?
|
| Taxoids | 2 | 2015 | 37 | 0.930 |
Why?
|
| Neoplasms | 4 | 2022 | 809 | 0.920 |
Why?
|
| Selenomethionine | 3 | 2015 | 5 | 0.910 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 413 | 0.900 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2013 | 21 | 0.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 409 | 0.810 |
Why?
|
| Ampicillin | 1 | 2020 | 14 | 0.700 |
Why?
|
| Listeria monocytogenes | 1 | 2020 | 59 | 0.670 |
Why?
|
| Endothelial Cells | 3 | 2013 | 352 | 0.670 |
Why?
|
| Molecular Targeted Therapy | 3 | 2016 | 135 | 0.660 |
Why?
|
| Organoselenium Compounds | 3 | 2015 | 8 | 0.640 |
Why?
|
| Methanol | 3 | 2015 | 14 | 0.640 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 679 | 0.620 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.560 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 41 | 0.540 |
Why?
|
| Annexin A1 | 1 | 2016 | 3 | 0.540 |
Why?
|
| Glucuronidase | 1 | 2016 | 9 | 0.540 |
Why?
|
| Sirolimus | 1 | 2017 | 76 | 0.520 |
Why?
|
| Humans | 22 | 2024 | 28097 | 0.510 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 163 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 524 | 0.500 |
Why?
|
| Flucytosine | 2 | 2015 | 2 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 330 | 0.480 |
Why?
|
| Enzymes | 1 | 2015 | 23 | 0.480 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 48 | 0.440 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 277 | 0.420 |
Why?
|
| Animals | 10 | 2024 | 10423 | 0.410 |
Why?
|
| Mice | 7 | 2024 | 4654 | 0.410 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 298 | 0.400 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 589 | 0.370 |
Why?
|
| Infrared Rays | 1 | 2011 | 24 | 0.370 |
Why?
|
| Cell Survival | 6 | 2013 | 409 | 0.370 |
Why?
|
| Female | 10 | 2024 | 15156 | 0.360 |
Why?
|
| Receptors, Cell Surface | 3 | 2007 | 114 | 0.360 |
Why?
|
| Neoplasm Metastasis | 2 | 2024 | 162 | 0.350 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 7 | 0.340 |
Why?
|
| Genetic Therapy | 1 | 2011 | 123 | 0.340 |
Why?
|
| Immunotherapy | 2 | 2024 | 161 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 269 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 540 | 0.310 |
Why?
|
| Kinetics | 3 | 2016 | 545 | 0.300 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 325 | 0.300 |
Why?
|
| Drug Synergism | 2 | 2018 | 104 | 0.280 |
Why?
|
| Proteins | 1 | 2010 | 252 | 0.280 |
Why?
|
| Protein Binding | 3 | 2013 | 658 | 0.250 |
Why?
|
| Solubility | 3 | 2015 | 73 | 0.250 |
Why?
|
| Protein Stability | 2 | 2016 | 43 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 607 | 0.230 |
Why?
|
| Cells, Cultured | 3 | 2020 | 985 | 0.230 |
Why?
|
| Protein Conformation | 2 | 2016 | 257 | 0.230 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 39 | 0.220 |
Why?
|
| Photosensitizing Agents | 1 | 2024 | 35 | 0.220 |
Why?
|
| Models, Molecular | 2 | 2016 | 452 | 0.210 |
Why?
|
| Fluorouracil | 2 | 2015 | 58 | 0.210 |
Why?
|
| Phagocytosis | 1 | 2022 | 80 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 101 | 0.190 |
Why?
|
| Logistic Models | 2 | 2015 | 407 | 0.180 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 4 | 2009 | 11 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 178 | 0.180 |
Why?
|
| Phospholipids | 1 | 2020 | 76 | 0.170 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 65 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 148 | 0.170 |
Why?
|
| Apoptosis | 1 | 2022 | 775 | 0.150 |
Why?
|
| Nanomedicine | 1 | 2019 | 62 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2022 | 287 | 0.150 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 267 | 0.150 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2018 | 7 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2013 | 806 | 0.150 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 13 | 0.150 |
Why?
|
| OX40 Ligand | 1 | 2018 | 16 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 29 | 0.150 |
Why?
|
| Lasers | 1 | 2018 | 67 | 0.140 |
Why?
|
| Tissue Distribution | 1 | 2018 | 137 | 0.140 |
Why?
|
| Drug Delivery Systems | 4 | 2014 | 225 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2017 | 110 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 356 | 0.130 |
Why?
|
| Mutation | 3 | 2016 | 847 | 0.130 |
Why?
|
| Vidarabine | 1 | 2015 | 3 | 0.120 |
Why?
|
| Adenine | 1 | 2015 | 17 | 0.120 |
Why?
|
| Cell Death | 1 | 2015 | 118 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 103 | 0.110 |
Why?
|
| Enzyme Therapy | 1 | 2013 | 2 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2015 | 128 | 0.110 |
Why?
|
| Suspensions | 1 | 2013 | 6 | 0.110 |
Why?
|
| Maleimides | 1 | 2013 | 6 | 0.110 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2013 | 17 | 0.110 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 20 | 0.110 |
Why?
|
| Biotinylation | 1 | 2013 | 19 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2013 | 61 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 90 | 0.110 |
Why?
|
| Phosphatidylethanolamines | 1 | 2013 | 26 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2013 | 69 | 0.100 |
Why?
|
| Adsorption | 2 | 2010 | 32 | 0.100 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2013 | 74 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1576 | 0.100 |
Why?
|
| Cell Movement | 4 | 2009 | 373 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 163 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 168 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2013 | 259 | 0.090 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2011 | 32 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1461 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2011 | 5 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 113 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2379 | 0.090 |
Why?
|
| Photochemotherapy | 1 | 2011 | 42 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 86 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 120 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 391 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 115 | 0.090 |
Why?
|
| Aorta | 1 | 2011 | 124 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 300 | 0.080 |
Why?
|
| Sodium Cholate | 1 | 2010 | 2 | 0.080 |
Why?
|
| Databases, Protein | 1 | 2010 | 22 | 0.080 |
Why?
|
| Cell Growth Processes | 2 | 2007 | 18 | 0.080 |
Why?
|
| Bile Acids and Salts | 1 | 2010 | 23 | 0.080 |
Why?
|
| Glucose Oxidase | 1 | 2009 | 8 | 0.080 |
Why?
|
| Surface-Active Agents | 1 | 2010 | 44 | 0.080 |
Why?
|
| Surface Properties | 1 | 2010 | 134 | 0.080 |
Why?
|
| Peptides | 1 | 2011 | 288 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 43 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1991 | 174 | 0.080 |
Why?
|
| Cell Line | 1 | 2010 | 696 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 6 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 132 | 0.060 |
Why?
|
| Coagulants | 1 | 2005 | 7 | 0.060 |
Why?
|
| Thromboplastin | 1 | 2005 | 28 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2006 | 331 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2005 | 118 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2005 | 294 | 0.050 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 18 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 147 | 0.050 |
Why?
|
| Clathrin | 1 | 2022 | 20 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 62 | 0.050 |
Why?
|
| Disaccharides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2003 | 116 | 0.050 |
Why?
|
| Endocytosis | 1 | 2022 | 89 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 62 | 0.050 |
Why?
|
| Base Sequence | 1 | 2003 | 586 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 417 | 0.040 |
Why?
|
| Male | 2 | 2014 | 13491 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2022 | 226 | 0.040 |
Why?
|
| Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Research | 1 | 2019 | 92 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 769 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1991 | 26 | 0.020 |
Why?
|
| Chromatography | 1 | 1991 | 9 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 1991 | 12 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1991 | 131 | 0.020 |
Why?
|
| Enzymes, Immobilized | 1 | 2009 | 6 | 0.020 |
Why?
|
| Electrodes | 1 | 2009 | 72 | 0.020 |
Why?
|
| Polymers | 1 | 2009 | 117 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 365 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2007 | 202 | 0.020 |
Why?
|
| Factor VIIIa | 1 | 2005 | 2 | 0.020 |
Why?
|
| Factor X | 1 | 2005 | 11 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2005 | 35 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2005 | 59 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 284 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 265 | 0.010 |
Why?
|
| Methionine | 1 | 2003 | 37 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 99 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 154 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 126 | 0.010 |
Why?
|